WO2012040266A3 - Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines - Google Patents

Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines Download PDF

Info

Publication number
WO2012040266A3
WO2012040266A3 PCT/US2011/052460 US2011052460W WO2012040266A3 WO 2012040266 A3 WO2012040266 A3 WO 2012040266A3 US 2011052460 W US2011052460 W US 2011052460W WO 2012040266 A3 WO2012040266 A3 WO 2012040266A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
compositions
increase antibody
antibody production
response
Prior art date
Application number
PCT/US2011/052460
Other languages
French (fr)
Other versions
WO2012040266A2 (en
Inventor
Geoffrey William Stone
Saravana K. Kanagavelu
Original Assignee
University Of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Miami filed Critical University Of Miami
Publication of WO2012040266A2 publication Critical patent/WO2012040266A2/en
Publication of WO2012040266A3 publication Critical patent/WO2012040266A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

DNA vectors encoding IL-12, IL-21, and various soluble trimeric TNFSF ligands to increase antibody titers for DNA vaccines are disclosed herein. The DNA vectors include IL-12, IL-21, and TNFSF ligands, either individually or in particular combinations, and increase antibody production to the gpl40 protein of HIV- 1 and increase virus neutralizing antibodies to HIV-1. Compositions, kits, and methods comprising DNA vectors encoding IL-12, IL-21, and various soluble trimeric TNFSF ligands may be utilized in treating disorders or diseases and conditions such as HIV infection and cancer.
PCT/US2011/052460 2010-09-24 2011-09-21 Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines WO2012040266A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38614510P 2010-09-24 2010-09-24
US61/386,145 2010-09-24

Publications (2)

Publication Number Publication Date
WO2012040266A2 WO2012040266A2 (en) 2012-03-29
WO2012040266A3 true WO2012040266A3 (en) 2012-07-19

Family

ID=45874339

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/052460 WO2012040266A2 (en) 2010-09-24 2011-09-21 Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines

Country Status (1)

Country Link
WO (1) WO2012040266A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150130283A (en) 2013-03-15 2015-11-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Vaccines with biomolecular adjuvants
KR20230145241A (en) 2014-10-01 2023-10-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Vaccines having an antigen and interleukin-21 as an adjuvant
US20220257756A1 (en) * 2019-07-12 2022-08-18 Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd. Engineered vaccinia virus

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197305A1 (en) * 1997-12-11 2004-10-07 Alfredo Garzino-Demo Immuno-modulating effects of chemokines in dna vaccination
US20090053252A1 (en) * 1999-12-30 2009-02-26 Apotech Research And Development Ltd. Bimer or an oligomer of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins
US20090053299A1 (en) * 2007-07-09 2009-02-26 Georgetown University Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery
US20090069256A1 (en) * 2004-06-04 2009-03-12 Smith Larry R Enhancing protein expression
US20090081157A1 (en) * 2006-01-09 2009-03-26 Richard Syd Kornbluth Immunostimulatory Combinations for Vaccine Adjuvants
US20090208531A1 (en) * 2006-02-16 2009-08-20 National Institutes Of Health Office Of Technology Antiviral agents and vaccines against influenza
US20090238841A1 (en) * 2002-10-07 2009-09-24 John Donnelly Hiv vaccine formulations
US7655235B2 (en) * 2002-11-05 2010-02-02 Glaxo Group Limited Vaccine
US20100166787A1 (en) * 2006-07-28 2010-07-01 David B Weiner Vaccines and methods for using the same
US20100199364A1 (en) * 2007-07-10 2010-08-05 Oliver Hill Tnf superfamily collectin fusion proteins

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197305A1 (en) * 1997-12-11 2004-10-07 Alfredo Garzino-Demo Immuno-modulating effects of chemokines in dna vaccination
US20090053252A1 (en) * 1999-12-30 2009-02-26 Apotech Research And Development Ltd. Bimer or an oligomer of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins
US20090238841A1 (en) * 2002-10-07 2009-09-24 John Donnelly Hiv vaccine formulations
US7655235B2 (en) * 2002-11-05 2010-02-02 Glaxo Group Limited Vaccine
US20090069256A1 (en) * 2004-06-04 2009-03-12 Smith Larry R Enhancing protein expression
US20090081157A1 (en) * 2006-01-09 2009-03-26 Richard Syd Kornbluth Immunostimulatory Combinations for Vaccine Adjuvants
US20090208531A1 (en) * 2006-02-16 2009-08-20 National Institutes Of Health Office Of Technology Antiviral agents and vaccines against influenza
US20100166787A1 (en) * 2006-07-28 2010-07-01 David B Weiner Vaccines and methods for using the same
US20090053299A1 (en) * 2007-07-09 2009-02-26 Georgetown University Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery
US20100199364A1 (en) * 2007-07-10 2010-08-05 Oliver Hill Tnf superfamily collectin fusion proteins

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BOLESTA ET AL.: "Clustered epitopes within the Gag-Pol fusion protein DNA vaccine enhance immune responses and protection against challenge with recombinant vaccinia viruses expressing HIV-1 Gag and Pol antigens.", VIROLOGY, vol. 332, no. 2, 2005, pages 467 - 479 *
BOLESTA ET AL.: "Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery.", J IMMUNOLOGY, vol. 177, no. 1, 2006, pages 177 - 191 *
CAPUTO ET AL.: "HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.", INT REV IMMUNOL., vol. 28, no. 5, 2009, pages 285 - 334 *
CERUTTI ET AL.: "Role of BAFF and APRIL in Antibody Production and Diversification.", CONTEMPORARY IMMUNOLOGY. BLYS LIGANDS AND RECEPTORS, 2009, pages 65 - 92 *
GHERARDI ET AL.: "IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner.", J LMMUNOL., vol. 162, no. 11, 1999, pages 6724 - 33 *
HANLON ET AL.: "Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors.", J VIROL., vol. 75, no. 18, 2001, pages 8424 - 8433 *
HE ET AL.: "HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40- independent mechanism involving BAFF and C-type lectin receptors.", J LMMUNOL., vol. 176, no. 7, 2006, pages 3931 - 3941 *
MORROW ET AL.: "Comparative ability of IL12 and IL28B to regulate Treg populations and enhance adaptive cellular immunity.", BLOOD, vol. 113, no. 23, 2009, pages 5868 - 5877 *
RODRIGUES ET AL.: "IL-21 and IL-15 cytokine DNA augments HSV specific effector and memory CD8+ T cell response.", MOL IMMUNOL., vol. 46, no. 7, 2009, pages 1494 - 504 *
STONE ET AL.: "Macaque multimeric soluble CD40 ligand and GITR ligand'constructs are immunostimulatory molecules in vitro.", CLIN VACCINE IMMUNOL., vol. 13, no. 11, 2006, pages 1223 - 1230 *
STONE ET AL.: "Multimeric soluble CD40 ligand and GITR ligand as adjuvants for HIV DNA vaccines.", J. VIROL., vol. 80, no. 4, 2006, pages 1762 - 72 *

Also Published As

Publication number Publication date
WO2012040266A2 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
EP4043031A3 (en) Zika viral antigen constructs
WO2016037154A8 (en) Recombinant hiv-1 envelope proteins and their use
WO2017070620A3 (en) Broad spectrum influenza virus vaccine
WO2012106377A3 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
WO2010019262A3 (en) Polyvalent vaccine
BRPI0922867B8 (en) respiratory syncytial virus (rsv) fusion glycoprotein (f), isolated nucleic acid, host cell, vaccine composition and purified micelle
BR112013012555A2 (en) Immunogenic peptides for use in the prevention and / or treatment of infectious diseases, autoimmune diseases, immune responses to allopaths, allergic diseases, tumors, graft rejection, and immune responses against viral vectors used for gene therapy or gene vaccination.
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
EA201591287A1 (en) VACCINES CONTAINING STABILIZED TRIMMERS OF THE HUMAN IMMUNODEFICIENCY VIRUS VIRUS, AND METHODS OF THEIR USE
EA201391496A1 (en) IMMUNOGENIC COMPOSITIONS AND METHODS OF APPLICATION OF SUCH COMPOSITIONS FOR INDUCTION OF HUMORAL AND CELLULAR IMMUNE RESPONSE
WO2012061815A3 (en) RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
JP2011250797A5 (en)
WO2017218974A3 (en) Treatment of amd using aav2 variant with aflibercept
NZ718900A9 (en) Complex containing oligonucleotide having immunopotentiating activity and use thereof
WO2012099805A3 (en) Nanoparticle based immunological stimulation
MX2020001385A (en) Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same.
WO2013059524A3 (en) Antibodies directed against influenza
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2011109511A3 (en) Novel hiv-1 envelope glycoprotein
MX2019003615A (en) Nucleic acid molecule encoding hepatitis b virus core protein and surface antigen protein and vaccine comprising the same.
WO2009009759A3 (en) Yersinia pestis antigens, vaccine compositions, and related methods
EP2873423A3 (en) Soluble hiv-1 envelope glycoprotein trimers
WO2013110818A3 (en) Immunogens for hiv vaccination
EP2568289A3 (en) Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11827400

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11827400

Country of ref document: EP

Kind code of ref document: A2